Neurocrine Biosciences (NBIX) 37.22 $NBIX
Shares of NBIX Up 103.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Feb 10, 9:08AM CST
SmarTrend identified an Uptrend for Neurocrine Biosciences (NASDAQ:NBIX) on October 16th, 2014 at $16.88. In approximately 4 months, Neurocrine Biosciences has returned 103.82% as of today's recent price of $34.40.
NBIX: 37.22 (+0.27)
Neurocrine Biosciences' (NBIX) CEO Kevin Gorman on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Feb 09, 10:58PM CST
NBIX: 37.22 (+0.27)
Neurocrine reports 4Q loss
Automated Insights - Mon Feb 09, 3:21PM CST
SAN DIEGO (AP) _ Neurocrine Biosciences Inc. (NBIX) on Monday reported a loss of $19.4 million in its fourth quarter.
NBIX: 37.22 (+0.27)
Neurocrine Biosciences misses by $0.02
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 3:06PM CST
NBIX: 37.22 (+0.27)
Neurocrine Biosciences Reports Year-End 2014 Results and Provides Investor Update for 2015
PR Newswire - Mon Feb 09, 3:01PM CST
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter and year ended December 31, 2014.
NBIX: 37.22 (+0.27)
Notable earnings after Monday’s close
Seeking Alpha - at Seeking Alpha - Sun Feb 08, 4:35PM CST
CCK: 50.65 (+0.74), MXL: 8.37 (+0.09), TDW: 30.01 (+1.45), MOH: 59.66 (+0.26), DAC: 5.86 (-0.01), PRI: 55.09 (+0.55), ICUI: 88.98 (+0.42), NEWP: 20.29 (-0.01), CSC: 66.10 (+1.60), GSM: 15.60 (+0.06), QLYS: 47.95 (+1.46), AMAG: 41.49 (+0.23), AMKR: 8.90 (-0.02), NTES: 112.99 (-0.49), IPHI: 19.17 (-1.48), GIG: 1.19 (+0.05), ALSN: 31.88 (+0.24), KS: 32.52 (-0.35), SSNI: 9.15 (+0.36), CMP: 91.66 (+0.52), COUP: 11.06 (-0.07), MRH: 36.05 (-0.54), NBIX: 37.22 (+0.27), MODN: 11.64 (-0.01), RLD: 12.65 (+0.16), DNB: 133.27 (+0.46), WCN: 46.05 (-0.42), MCC: 9.44 (+0.15), CRK: 6.09 (+0.46), OTTR: 31.27 (unch), MERU: 2.74 (-0.01)
Neurocrine Biosciences to Present at the 2015 Leerink Global Healthcare Conference
PR Newswire - Wed Feb 04, 12:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Tim Coughlin, Chief Financial Officer of Neurocrine Biosciences, will be presenting at the 2015 Leerink Global Healthcare Conference in New York City.
NBIX: 37.22 (+0.27)
Neurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2014 Results
PR Newswire - Mon Feb 02, 12:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its fourth quarter and year-end 2014 results after the Nasdaq market closes on Monday, February 9, 2015. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Monday afternoon, February 9, 2015 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
NBIX: 37.22 (+0.27)
Shares of NBIX Up 99.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Feb 02, 9:08AM CST
SmarTrend identified an Uptrend for Neurocrine Biosciences (NASDAQ:NBIX) on October 16th, 2014 at $16.88. In approximately 4 months, Neurocrine Biosciences has returned 99.64% as of today's recent price of $33.70.
NBIX: 37.22 (+0.27)
Biotech Stocks Technical Analysis - Achillion Pharma, Array BioPharma, Rexahn Pharma, Neurocrine Biosciences, and Bluebird Bio
PR Newswire - Tue Jan 27, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Array BioPharma Inc. (NASDAQ: ARRY), Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and Bluebird Bio Inc. (NASDAQ: BLUE). Free research report on Achillion Pharma can be accessed at http://get.Investor-Edge.com/pdf/?c=Achillion...amp;s=ACHN. On Monday, January 26, 2015, the NASDAQ Composite ended at 4,771.76, up 0.29%, the Dow Jones Industrial Average advanced 0.03%, to finish the day at 17,678.70, and the S&P 500 closed at 2,057.09, up 0.26%. The gains were broad based as six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 825.01, up 0.45%, with the index also advancing 9.36% in the previous three months. Register for your complimentary reports at the links given below.
BLUE: 90.70 (+0.93), RNN: 0.75 (+0.01), NBIX: 37.22 (+0.27), ACHN: 10.89 (-0.20), ARRY: 8.05 (+0.08)
87.8% Return Seen to Date on SmarTrend Neurocrine Biosciences Call (NBIX)
Comtex SmarTrend(R) - Fri Jan 23, 4:37PM CST
SmarTrend identified an Uptrend for Neurocrine Biosciences (NASDAQ:NBIX) on October 16th, 2014 at $16.88. In approximately 3 months, Neurocrine Biosciences has returned 87.80% as of today's recent price of $31.70.
NBIX: 37.22 (+0.27)
Neurocrine Biosciences Announces Oral Presentation of NBI-77860 Clinical Trial Data in Classic Congenital Adrenal Hyperplasia at ENDO 2015
PR Newswire - Tue Jan 20, 7:00AM CST
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the steering committee of ENDO 2015 has selected the abstract of their recently completed clinical study of NBI-77860 in classic congenital adrenal hyperplasia for an oral presentation on the initial day of the Endocrine Society's 97th Annual Meeting. ENDO is the world's largest endocrinology meeting drawing over 10,000 experts from around the world. The ENDO 2015 meeting will be held in San Diego from March 5-8, 2015.
NBIX: 37.22 (+0.27)
Neurocrine Biosciences wins US FDA orphan drug status for NBI-77860 for congenital adrenal hyperplasia
M2 - Mon Jan 19, 6:39AM CST
Pharmaceuticals company Neurocrine Biosciences (NasdaqGS:NBIX) reported on Friday the receipt of orphan drug status from the US Food and Drug Administration (FDA) for NBI-77860 for the treatment of congenital adrenal hyperplasia (CAH) a disease that affects approximately 20,000-30,000 people in the US.
NBIX: 37.22 (+0.27)
Neurocrine Biosciences Announces Granting of Orphan Drug Status for NBI-77860 in Congenital Adrenal Hyperplasia
PR Newswire - Fri Jan 16, 1:30PM CST
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that NBI-77860, a proprietary corticotropin releasing factor 1 (CRF) receptor antagonist, has been granted orphan drug status by the United States Food and Drug Administration (FDA) for the treatment of congenital adrenal hyperplasia (CAH) a disease that affects approximately 20,000-30,000 people in the United States.
NBIX: 37.22 (+0.27)
Critical Alerts For Zynga, Neurocrine Biosciences, Yum! Brands, eBay and TrueCar Released By InvestorsObserver
PR Newswire - Mon Jan 12, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for ZNGA, NBIX, YUM, EBAY and TRUE.
NBIX: 37.22 (+0.27), EBAY: 56.47 (+1.73), TRUE: 19.55 (+0.12), ZNGA: 2.24 (-0.42), YUM: 74.69 (-0.11)
Cancel JPMorgan! Plenty of Pre-Conference Data and Deals to Digest
Brian Orelli, The Motley Fool - Motley Fool - Sat Jan 10, 6:49AM CST
JPMorgan 's annual healthcare conference is set to kick off next week, but many companies already announced clinical trial data and deals ahead of the conference. Part of the early release has to do with SEC regulations. In addition to public...
BIIB: 391.66 (-0.45), VRTX: 113.66 (+4.03), PFE: 34.64 (-0.23), INCY: 75.94 (+0.28), AMGN: 153.48 (+0.30), BMY: 60.04 (+0.56), ALKS: 71.40 (-1.89), CELG: 115.88 (+0.16), AGEN: 5.03 (-0.01), JNJ: 99.62 (+1.18), NBIX: 37.22 (+0.27), JPM: 59.67 (+0.10), ISIS: 63.86 (-0.43), ALNY: 95.54 (+1.67), KITE: 62.59 (+0.82), GILD: 101.90 (+1.10), GWPH: 78.09 (+1.70), INFI: 15.13 (+0.55), ABBV: 58.05 (+1.00), CEMP: 27.68 (+1.25), SNY: 49.42 (+0.82), ARNA: 4.55 (+0.02), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 4:35PM CST
NBIX: 37.22 (+0.27), ROC: 79.20 (+0.33), RUSL: 27.31 (+1.68), RUSS: 11.59 (-0.81), EHIC: 10.48 (-0.01), BURL: 51.91 (-0.56), POZN: 6.95 (+0.15), EXK: 2.48 (+0.08), SEM: 14.32 (+0.11), MCO: 98.22 (+0.01)
Seeking Alpha's Biotech Weekly: Gilead Rises With Phenex, Bass's Patent Attack, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 09, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
AGEN: 5.03 (-0.01), JNJ: 99.62 (+1.18), NBIX: 37.22 (+0.27), ISIS: 63.86 (-0.43), KITE: 62.59 (+0.82), GILD: 101.90 (+1.10), INCY: 75.94 (+0.28), CVS: 102.63 (-0.37), AMGN: 153.48 (+0.30), ABBV: 58.05 (+1.00), ARNA: 4.55 (+0.02), NVS: 102.20 (-0.17)
AbbVie Stock Down After Guidance, Downgrade
at Investor's Business Daily - Fri Jan 09, 10:49AM CST
Shares of big pharma AbbVie (ABBV) dropped more than 3% Friday morning after the company issued 2015 EPS guidance and got downgraded by Bank of America. AbbVie said it expects full-year earnings of $4.25 to $4.45, the midpoint just above the average...
ANTM: 141.05 (-0.95), IMS: 25.68 (+0.22), ESRX: 84.90 (+0.40), NBIX: 37.22 (+0.27), GILD: 101.90 (+1.10), CVS: 102.63 (-0.37), ABBV: 58.05 (+1.00)
Shares of NBIX Up 103.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Feb 10, 9:08AM CST
SmarTrend identified an Uptrend for Neurocrine Biosciences (NASDAQ:NBIX) on October 16th, 2014 at $16.88. In approximately 4 months, Neurocrine Biosciences has returned 103.82% as of today's recent price of $34.40.
NBIX: 37.22 (+0.27)
Neurocrine Biosciences' (NBIX) CEO Kevin Gorman on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Feb 09, 10:58PM CST
NBIX: 37.22 (+0.27)
Neurocrine reports 4Q loss
Automated Insights - Mon Feb 09, 3:21PM CST
SAN DIEGO (AP) _ Neurocrine Biosciences Inc. (NBIX) on Monday reported a loss of $19.4 million in its fourth quarter.
NBIX: 37.22 (+0.27)
Neurocrine Biosciences misses by $0.02
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 3:06PM CST
NBIX: 37.22 (+0.27)
Neurocrine Biosciences Reports Year-End 2014 Results and Provides Investor Update for 2015
PR Newswire - Mon Feb 09, 3:01PM CST
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter and year ended December 31, 2014.
NBIX: 37.22 (+0.27)
Notable earnings after Monday’s close
Seeking Alpha - at Seeking Alpha - Sun Feb 08, 4:35PM CST
CCK: 50.65 (+0.74), MXL: 8.37 (+0.09), TDW: 30.01 (+1.45), MOH: 59.66 (+0.26), DAC: 5.86 (-0.01), PRI: 55.09 (+0.55), ICUI: 88.98 (+0.42), NEWP: 20.29 (-0.01), CSC: 66.10 (+1.60), GSM: 15.60 (+0.06), QLYS: 47.95 (+1.46), AMAG: 41.49 (+0.23), AMKR: 8.90 (-0.02), NTES: 112.99 (-0.49), IPHI: 19.17 (-1.48), GIG: 1.19 (+0.05), ALSN: 31.88 (+0.24), KS: 32.52 (-0.35), SSNI: 9.15 (+0.36), CMP: 91.66 (+0.52), COUP: 11.06 (-0.07), MRH: 36.05 (-0.54), NBIX: 37.22 (+0.27), MODN: 11.64 (-0.01), RLD: 12.65 (+0.16), DNB: 133.27 (+0.46), WCN: 46.05 (-0.42), MCC: 9.44 (+0.15), CRK: 6.09 (+0.46), OTTR: 31.27 (unch), MERU: 2.74 (-0.01)
Neurocrine Biosciences to Present at the 2015 Leerink Global Healthcare Conference
PR Newswire - Wed Feb 04, 12:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Tim Coughlin, Chief Financial Officer of Neurocrine Biosciences, will be presenting at the 2015 Leerink Global Healthcare Conference in New York City.
NBIX: 37.22 (+0.27)
Neurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2014 Results
PR Newswire - Mon Feb 02, 12:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its fourth quarter and year-end 2014 results after the Nasdaq market closes on Monday, February 9, 2015. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Monday afternoon, February 9, 2015 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
NBIX: 37.22 (+0.27)
Shares of NBIX Up 99.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Feb 02, 9:08AM CST
SmarTrend identified an Uptrend for Neurocrine Biosciences (NASDAQ:NBIX) on October 16th, 2014 at $16.88. In approximately 4 months, Neurocrine Biosciences has returned 99.64% as of today's recent price of $33.70.
NBIX: 37.22 (+0.27)
Biotech Stocks Technical Analysis - Achillion Pharma, Array BioPharma, Rexahn Pharma, Neurocrine Biosciences, and Bluebird Bio
PR Newswire - Tue Jan 27, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Array BioPharma Inc. (NASDAQ: ARRY), Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and Bluebird Bio Inc. (NASDAQ: BLUE). Free research report on Achillion Pharma can be accessed at http://get.Investor-Edge.com/pdf/?c=Achillion...amp;s=ACHN. On Monday, January 26, 2015, the NASDAQ Composite ended at 4,771.76, up 0.29%, the Dow Jones Industrial Average advanced 0.03%, to finish the day at 17,678.70, and the S&P 500 closed at 2,057.09, up 0.26%. The gains were broad based as six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 825.01, up 0.45%, with the index also advancing 9.36% in the previous three months. Register for your complimentary reports at the links given below.
BLUE: 90.70 (+0.93), RNN: 0.75 (+0.01), NBIX: 37.22 (+0.27), ACHN: 10.89 (-0.20), ARRY: 8.05 (+0.08)
87.8% Return Seen to Date on SmarTrend Neurocrine Biosciences Call (NBIX)
Comtex SmarTrend(R) - Fri Jan 23, 4:37PM CST
SmarTrend identified an Uptrend for Neurocrine Biosciences (NASDAQ:NBIX) on October 16th, 2014 at $16.88. In approximately 3 months, Neurocrine Biosciences has returned 87.80% as of today's recent price of $31.70.
NBIX: 37.22 (+0.27)
Neurocrine Biosciences Announces Oral Presentation of NBI-77860 Clinical Trial Data in Classic Congenital Adrenal Hyperplasia at ENDO 2015
PR Newswire - Tue Jan 20, 7:00AM CST
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the steering committee of ENDO 2015 has selected the abstract of their recently completed clinical study of NBI-77860 in classic congenital adrenal hyperplasia for an oral presentation on the initial day of the Endocrine Society's 97th Annual Meeting. ENDO is the world's largest endocrinology meeting drawing over 10,000 experts from around the world. The ENDO 2015 meeting will be held in San Diego from March 5-8, 2015.
NBIX: 37.22 (+0.27)
Neurocrine Biosciences wins US FDA orphan drug status for NBI-77860 for congenital adrenal hyperplasia
M2 - Mon Jan 19, 6:39AM CST
Pharmaceuticals company Neurocrine Biosciences (NasdaqGS:NBIX) reported on Friday the receipt of orphan drug status from the US Food and Drug Administration (FDA) for NBI-77860 for the treatment of congenital adrenal hyperplasia (CAH) a disease that affects approximately 20,000-30,000 people in the US.
NBIX: 37.22 (+0.27)
Neurocrine Biosciences Announces Granting of Orphan Drug Status for NBI-77860 in Congenital Adrenal Hyperplasia
PR Newswire - Fri Jan 16, 1:30PM CST
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that NBI-77860, a proprietary corticotropin releasing factor 1 (CRF) receptor antagonist, has been granted orphan drug status by the United States Food and Drug Administration (FDA) for the treatment of congenital adrenal hyperplasia (CAH) a disease that affects approximately 20,000-30,000 people in the United States.
NBIX: 37.22 (+0.27)
Critical Alerts For Zynga, Neurocrine Biosciences, Yum! Brands, eBay and TrueCar Released By InvestorsObserver
PR Newswire - Mon Jan 12, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for ZNGA, NBIX, YUM, EBAY and TRUE.
NBIX: 37.22 (+0.27), EBAY: 56.47 (+1.73), TRUE: 19.55 (+0.12), ZNGA: 2.24 (-0.42), YUM: 74.69 (-0.11)
Cancel JPMorgan! Plenty of Pre-Conference Data and Deals to Digest
Brian Orelli, The Motley Fool - Motley Fool - Sat Jan 10, 6:49AM CST
JPMorgan 's annual healthcare conference is set to kick off next week, but many companies already announced clinical trial data and deals ahead of the conference. Part of the early release has to do with SEC regulations. In addition to public...
BIIB: 391.66 (-0.45), VRTX: 113.66 (+4.03), PFE: 34.64 (-0.23), INCY: 75.94 (+0.28), AMGN: 153.48 (+0.30), BMY: 60.04 (+0.56), ALKS: 71.40 (-1.89), CELG: 115.88 (+0.16), AGEN: 5.03 (-0.01), JNJ: 99.62 (+1.18), NBIX: 37.22 (+0.27), JPM: 59.67 (+0.10), ISIS: 63.86 (-0.43), ALNY: 95.54 (+1.67), KITE: 62.59 (+0.82), GILD: 101.90 (+1.10), GWPH: 78.09 (+1.70), INFI: 15.13 (+0.55), ABBV: 58.05 (+1.00), CEMP: 27.68 (+1.25), SNY: 49.42 (+0.82), ARNA: 4.55 (+0.02), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 4:35PM CST
NBIX: 37.22 (+0.27), ROC: 79.20 (+0.33), RUSL: 27.31 (+1.68), RUSS: 11.59 (-0.81), EHIC: 10.48 (-0.01), BURL: 51.91 (-0.56), POZN: 6.95 (+0.15), EXK: 2.48 (+0.08), SEM: 14.32 (+0.11), MCO: 98.22 (+0.01)
Seeking Alpha's Biotech Weekly: Gilead Rises With Phenex, Bass's Patent Attack, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 09, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
AGEN: 5.03 (-0.01), JNJ: 99.62 (+1.18), NBIX: 37.22 (+0.27), ISIS: 63.86 (-0.43), KITE: 62.59 (+0.82), GILD: 101.90 (+1.10), INCY: 75.94 (+0.28), CVS: 102.63 (-0.37), AMGN: 153.48 (+0.30), ABBV: 58.05 (+1.00), ARNA: 4.55 (+0.02), NVS: 102.20 (-0.17)
AbbVie Stock Down After Guidance, Downgrade
at Investor's Business Daily - Fri Jan 09, 10:49AM CST
Shares of big pharma AbbVie (ABBV) dropped more than 3% Friday morning after the company issued 2015 EPS guidance and got downgraded by Bank of America. AbbVie said it expects full-year earnings of $4.25 to $4.45, the midpoint just above the average...
ANTM: 141.05 (-0.95), IMS: 25.68 (+0.22), ESRX: 84.90 (+0.40), NBIX: 37.22 (+0.27), GILD: 101.90 (+1.10), CVS: 102.63 (-0.37), ABBV: 58.05 (+1.00)
